Simulations Plus (NASDAQ:SLP) Issues FY 2026 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.030-1.100 for the period, compared to the consensus earnings per share estimate of 1.010. The company issued revenue guidance of $79.0 million-$82.0 million, compared to the consensus revenue estimate of $79.6 million.

Simulations Plus Stock Performance

Shares of SLP opened at $19.80 on Thursday. The company has a market capitalization of $398.97 million, a P/E ratio of -6.15 and a beta of 1.16. The business’s 50-day moving average is $17.21 and its two-hundred day moving average is $17.14. Simulations Plus has a fifty-two week low of $12.39 and a fifty-two week high of $37.67.

Simulations Plus (NASDAQ:SLP) last issued its earnings results on Monday, December 1st. The technology company reported $0.10 EPS for the quarter, hitting analysts’ consensus estimates of $0.10. Simulations Plus had a positive return on equity of 13.27% and a negative net margin of 81.74%.The firm had revenue of $17.46 million for the quarter, compared to the consensus estimate of $17.41 million. During the same quarter in the prior year, the business earned $0.06 earnings per share. Analysts forecast that Simulations Plus will post 1.09 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on SLP shares. Citigroup reiterated a “market perform” rating on shares of Simulations Plus in a research note on Tuesday, October 28th. KeyCorp reiterated a “sector weight” rating on shares of Simulations Plus in a research report on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Simulations Plus in a research report on Wednesday, October 8th. Zacks Research upgraded Simulations Plus from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. Finally, TD Cowen initiated coverage on Simulations Plus in a research report on Tuesday, September 30th. They set a “hold” rating and a $16.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $24.40.

Institutional Investors Weigh In On Simulations Plus

A number of institutional investors have recently made changes to their positions in SLP. Raymond James Financial Inc. purchased a new stake in shares of Simulations Plus in the 2nd quarter valued at $25,000. Quarry LP acquired a new position in Simulations Plus in the 3rd quarter valued at about $28,000. US Bancorp DE grew its position in Simulations Plus by 32.5% in the 3rd quarter. US Bancorp DE now owns 6,167 shares of the technology company’s stock valued at $93,000 after acquiring an additional 1,513 shares in the last quarter. PharVision Advisers LLC purchased a new stake in Simulations Plus during the third quarter worth about $155,000. Finally, First Trust Advisors LP acquired a new stake in shares of Simulations Plus during the third quarter worth about $167,000. 78.08% of the stock is currently owned by institutional investors and hedge funds.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.